S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
ACB   2.60 (+6.12%)
BAC   34.68 (+3.09%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
ACB   2.60 (+6.12%)
BAC   34.68 (+3.09%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
ACB   2.60 (+6.12%)
BAC   34.68 (+3.09%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
ACB   2.60 (+6.12%)
BAC   34.68 (+3.09%)
DIS   147.76 (+0.12%)
Log in

NASDAQ:ADMP - Adamis Pharmaceuticals Stock Price, Forecast & News

$0.52
-0.01 (-1.89 %)
(As of 12/12/2019 04:00 PM ET)
Today's Range
$0.51
Now: $0.52
$0.52
50-Day Range
$0.52
MA: $0.77
$1.26
52-Week Range
$0.48
Now: $0.52
$3.29
Volume577,350 shs
Average Volume821,824 shs
Market Capitalization$32.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMP
CUSIPN/A
Phone858-997-2400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.09 million
Book Value$0.99 per share

Profitability

Net Income$-39,010,000.00
Net Margins-175.77%

Miscellaneous

Employees152
Market Cap$32.05 million
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable

Receive ADMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMP and its competitors with MarketBeat's FREE daily newsletter.


Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) announced its quarterly earnings data on Tuesday, November, 12th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.06. The specialty pharmaceutical company had revenue of $5.90 million for the quarter, compared to analysts' expectations of $6.55 million. Adamis Pharmaceuticals had a negative net margin of 175.77% and a negative return on equity of 90.00%. View Adamis Pharmaceuticals' Earnings History.

When is Adamis Pharmaceuticals' next earnings date?

Adamis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Adamis Pharmaceuticals.

What price target have analysts set for ADMP?

4 equities research analysts have issued twelve-month target prices for Adamis Pharmaceuticals' shares. Their forecasts range from $1.10 to $6.00. On average, they expect Adamis Pharmaceuticals' stock price to reach $3.70 in the next twelve months. This suggests a possible upside of 611.5% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.

What is the consensus analysts' recommendation for Adamis Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamis Pharmaceuticals.

Has Adamis Pharmaceuticals been receiving favorable news coverage?

News stories about ADMP stock have been trending somewhat negative on Thursday, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Adamis Pharmaceuticals earned a news impact score of -1.7 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Adamis Pharmaceuticals.

Who are some of Adamis Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamis Pharmaceuticals own?

Who are Adamis Pharmaceuticals' key executives?

Adamis Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard C. Williams, Chairman & Consultant (Age 75)
  • Dr. Dennis J. Carlo, Pres, CEO & Director (Age 76)
  • Mr. Robert O. Hopkins, VP of Fin., CFO & Sec. (Age 59)
  • Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 49)
  • Mr. Robert B. Rothermel, Consultant & Director (Age 75)

Who are Adamis Pharmaceuticals' major shareholders?

Adamis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.14%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert B Rothermel, Robert O Hopkins and Ronald B Moss. View Institutional Ownership Trends for Adamis Pharmaceuticals.

Which institutional investors are buying Adamis Pharmaceuticals stock?

ADMP stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Adamis Pharmaceuticals.

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $0.52.

How big of a company is Adamis Pharmaceuticals?

Adamis Pharmaceuticals has a market capitalization of $32.05 million and generates $15.09 million in revenue each year. The specialty pharmaceutical company earns $-39,010,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Adamis Pharmaceuticals employs 152 workers across the globe.View Additional Information About Adamis Pharmaceuticals.

What is Adamis Pharmaceuticals' official website?

The official website for Adamis Pharmaceuticals is http://www.adamispharmaceuticals.com/.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]


MarketBeat Community Rating for Adamis Pharmaceuticals (NASDAQ ADMP)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  473
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: Oversold

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel